Previous Article | Next Article ![]()
Antimicrobial Agents and Chemotherapy, March 2007, p. 1107-1108, Vol. 51, No. 3
0066-4804/07/$08.00+0 doi:10.1128/AAC.01320-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Infectious Disease,1 Infection Control Departments, Austin Health,2 Victoria Police,3 Victorian Institute of Forensic Medicine, Melbourne,4 Department of Epidemiology and Preventive Medicine, Monash University, Melbourne,5 Department of Medicine, University of Melbourne, Melbourne, Victoria 3084, Australia6
Received 23 October 2006/ Returned for modification 22 November 2006/ Accepted 17 December 2006
|
|
|---|
|
|
|---|
(Presented in part at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 2006).
Consenting HCW volunteers completed a questionnaire recording their age, height, weight, gender, ethnicity, alcohol consumption during the 24 h prior to the study, and prescribed medication usage. Participants' heights and weights were used to calculate their body mass indexes (BMI). HCWs were excluded if they had a evidence of chronic dermatitis (e.g., eczema) or broken/damaged skin or a history of allergy to ABHRS or were currently pregnant.
We assessed two commonly used ABHRS that contained 0.5% chlorhexidine gluconate, a skin emollient and either 70% ETOH (Avagard; 3M Healthcare, Pymble, Australia) or 70% ISOP (DeBug; Orion Laboratories Pty Ltd., Balcatta, Australia) (4, 13). To mimic intensive clinical conditions, HCWs used ABHRS 30 times during a 1-h period on two separate days, with a 1 day "washout" period between (day 1, Avagard use; day 2, washout; day 3, DeBug use). Supervisors coordinated, timed, and advised all participants when to reapply ABHRS and ensured compliance with the correct application (one squirt [1.2 to 1.5 ml] every 2 min) of ABHRS (13). Study room conditions were as follows: room temperature, 24 to 26°C; humidity, 39 to 42%; study room volume, 124 cubic meters.
Breath and serum alcohol levels were assessed as follows. Preexposure (baseline), breath and serum alcohol levels were assessed. Postexposure (time after last application of ABHRS), at 1 to 2 min, breath levels only were tested; at 5 to 7 min, serum levels only were tested; and 10 to 13 min, breath levels only were tested. Breath alcohol levels were assessed by police from the Traffic Alcohol Section, Victoria Police, using a Drager Alcotest 7110 breathalyzer (lower limit of detection, 0.001%), as is used by Victoria Police for all evidential breath alcohol analysis, following preliminary roadside breath testing using a hand-held screening device. Results from this breathalyzer are sufficiently accurate to be legally admissible in court and obviate the need for serum ETOH assessment. The breathalyzer detects ETOH but not ISOP. All breathalyzer analyses were undertaken in a room distant from where ABHRS was in use to avoid potential vapor contamination of breath alcohol tests.
Serum ETOH and ISOP levels were assessed by gas chromatography (lower limit of quantitation, 0.002 g/100 ml [%]; lower limit of detection: 0.0001 g/100 ml [%] for both alcohols) at the Victorian Institute of Forensic Medicine, where all serum/blood alcohol assessments are undertaken for the State Coroner of Victoria. Serum specimens were collected in routine sodium fluoride/EDTA venipuncture tubes and stored at 4°C until analysis. Alcohol-containing skin cleansers were not used to swab the skin before venipuncture. The study protocol was approved by our institution's Human Ethics Committee.
Twenty HCWs (mean age, 40 ± 13 years [median, 36 years; range, 22 to 67 years]; 14 females; ethnic distribution, 18 Caucasian, 2 Asian) participated in the study. Participants' mean BMI was 26 ± 4 (median, 24; range, 21 to 34; acceptable BMI, n = 11; overweight BMI, n = 4; obese BMI, n = 5) (6). One HCW, who regularly used DeBug without any adverse reactions prior to this study, developed a severe cutaneous reaction to Avagard after day 1 such that she could not participate on day 3. Thus, 20 HCWs completed use of Avagard and 19 used DeBug in the study. Both ABHRS groups were sampled at similar times postexposure (mean ± standard deviation minutes after last application: ETOH, 2.3 ± 1.2, 6.4 ± 1.6, and 13.4 ± 1.7; ISOP, 1.9 ± 1.2, 7.1 ± 1.6, and 12.0 ± 1.7).
Results are shown in Table 1. ETOH levels were detectable in breath analysis of 6 of the 20 HCWs (range, 0.0010% to 0.0025%) at 1 to 2 min after the final application of Avagard: all would have been recorded as undetectable by Victoria Police performing routine roadside breathalyzer testing. However, two of these six HCWs also had detectable serum ETOH levels at 5 to 7 min postexposure. All breath ETOH levels were zero at 10 to 13 min after Avagard use. Measurable ETOH levels were not associated with HCW age, sex, ethnicity, or BMI, but statistical power was limited due to the low number of participants with detectable levels. All serum ISOP levels were unrecordable at each time point.
|
View this table: [in a new window] |
TABLE 1. Breath and serum alcohol levels before and after intensive use of alcohol-based hand-rub solution
|
Our findings appear to differ from those of Turner et al. who detected small levels of ISOP (0.5 to 1.8 mg/liter) in 9 of 10 participants after using ABHRS six times per h for 4 h (11). However, the assay they used had a lower limit of detection of 0.0005% (one dilution more sensitive than our assay) and a number of their participants had very low ISOP levels (0.0005% to 0.001%). Secondly, they applied a larger volume (3 ml) of 52.6% ISOP-containing ABHRS and did not wash their hands with soap and water for >4 h.
Our study has some limitations. First, since 9/20 HCWs were either overweight or obese, we cannot be sure whether lower-body-weight HCWs might not have higher levels. Secondly, we did not assess the routine alcohol consumption of our HCWs and therefore cannot be certain of the impact of increased alcohol metabolism on serum levels. Finally, we cannot be sure that intensive ABHRS use for longer than 1 h without washing may not result in higher absorption or accumulation rates (4, 10, 13).
Although there are many reasons described by HCWs regarding why they exhibit poor hand hygiene compliance (3, 7, 8, 9, 12), fear of alcohol absorption and loss of one's drivers license is no longer valid. Since ISOP appears slightly more predictable in its lack of cutaneous absorption than ETOH, ISOP-containing ABHRS may be preferred by some HCWs and religious groups.
There are no conflicts of interest. However, DeBug (a trademark for one of the hand hygiene product referred to in this article) was developed by some of the authors (employees of Austin Health) with funding in part from the Department of Human Services, Victoria, Australia. The intellectual property for this development is held by Austin Health, which handles all patent, trademark, and licensing issues. Austin Health, but no individual author, receives a small income stream from the sale of DeBug.
Published ahead of print on 28 December 2006. ![]()
|
|
|---|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»